Postdoctoral Scholarship in Preclinical Radioligand Development for Theranostic Applications

The University of Antwerp, a leading institution in Belgium, is offering a postdoctoral scholarship in preclinical radioligand development for theranostic applications. This position is hosted by the Center for Radiopharmaceuticals Antwerp (CREANT) and the Molecular Imaging Center Antwerp (MICA), both part of the Faculty of Medicine & Health Sciences. The successful candidate will join a dynamic and multidisciplinary team focused on advancing cancer research through the development and evaluation of novel radioligands targeting tumor-associated proteases. The project centers on the preclinical evaluation of FAP-targeted radioligands (FAPIs), which have demonstrated improved tumor retention and pharmacokinetics. The research aims to further enhance these ligands by conjugating them with alpha-emitting radionuclides, enabling precise and potent destruction of tumor tissue while minimizing damage to healthy organs. The ultimate goal is to generate robust preclinical data to support the translation of this therapeutic approach into a Phase I clinical trial. Key responsibilities include designing, planning, and executing preclinical experiments in cell and animal models of cancer, conducting biodistribution, dosimetry, and therapeutic efficacy studies of radiolabeled-FAPI conjugates, and performing molecular and histological analyses of treatment effects on the tumor microenvironment. The postdoctoral researcher will collaborate closely with radiochemistry, imaging, and oncology teams within the consortium and contribute to scientific publications, reports, and presentations at international conferences. Applicants must hold a PhD in oncology, cancer biology, pharmacology, radiobiology, radiopharmacy, pharmaceutical sciences, or a related field from a non-Belgian institution. Strong expertise in preclinical animal models (rodents), tumor biology, and therapeutic testing is required, along with hands-on experience in cell culture and in vitro assays. Experience in small animal imaging and previous work with radiopharmaceuticals is advantageous. Candidates should demonstrate the ability to work independently and collaboratively in a multidisciplinary environment, possess excellent scientific writing and communication skills in English, and align with the university’s research policies. The position offers a full-time appointment for one year, with the possibility of extension up to three years following positive evaluation. The monthly scholarship amount is determined according to the university’s pay scales for Contract Research Staff (BAP). Additional benefits include ecocheques, a bicycle allowance, or full reimbursement of public transport costs for commuting. The work will be conducted at the Laboratories of Radiopharmacy and MICA at campus Drie Eiken, providing access to state-of-the-art preclinical imaging and radiochemistry facilities. Applications are accepted via the University of Antwerp’s online job application platform. Candidates should submit a motivation letter, academic CV, and names and contact details of at least two referees. Applications are reviewed on a rolling basis until the position is filled. For questions regarding the application process, contact [email protected]. For job-specific inquiries, contact Prof. Filipe Elvas at [email protected]. The University of Antwerp is committed to diversity, inclusion, and equal opportunities, and encourages candidates from diverse backgrounds to apply. The institution has received the European Commission’s HR Excellence in Research Award and offers a supportive, family-friendly working environment that invests in employee growth and development.